NCT05777603View on ClinicalTrials.gov

Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 18, 2024

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2028

Conditions
Advanced Non Small Cell Lung Cancer
Interventions
DRUG

aerosolized aztreonam

antibiotic with gram-negative bacteria coverage

DRUG

aerosolized vancomycin

antibiotic with gram-positive bacteria coverage

DRUG

pembrolizumab

standard of care therapy/monoclonal antibody for patients with advanced NSCLC

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH